The heart of the matter
Tuesday, 11 October 2011
Kathleen Armstrong looks at developments
in cardiac patient monitoring that are improving
both the diagnosis and treatment of cardiovascular disease (CVD).
The market for cardiac patient monitoring devices market is
growing, driven by unhealthy lifestyles, an ageing population,
and the consequent increase in cardiovascular disease (CVD).
But the main reason is growth in the demand for easy-to-use,
patient-friendly devices that enable rapid and
robust diagnoses of CVD, according to a recent report
from Frost & Sullivan1.
Robert Clark, general manager of Draeger UK,
says one of the major advances is the improvement in networking
and the delivery of information.
All of its patient monitoring devices are WiFi-enabled
so patients can be monitored from wherever there is WiFi access in the trust.
Draeger’s Infinity M300 is a telemetry device which is worn
by the patient and continues to communicate with a trust’s network
via the Infinity CentralStation wherever the patient is in the hospital.
It means the patient can continued to be monitored
when they go to the physiotherapist or for tests.
“This gives the patient more flexibility and, because it continues
to monitor them, it can catch the episode that you want to capture,”
Clark says. At Derriford Hospital in Plymouth,
where the trust uses Draeger’s Infinity Omega solution, patients are
equipped with the telemetry device for a 24-hour assessment.
Because the information has been gathered without a break and
is captured online, where it can be accessed by the cardiologist,
the patient no longer has to undergo a second session of monitoring
when they go to the cardiologist.
“Hospitals are now re-thinking their care processes,” Clark comments.
Unimedic’s Arteriograph is a groundbreaking technology
that has advanced the way cardiac monitoring is undertaken.
Using a non-invasive catherisation method
with the help of a single arm cuff, the Arteriograph takes two minutes
to measure individual cardiovascular risk and
evaluate the efficiency of applied therapy.
The device provides information on central and
peripheral blood pressure, endothelial function, arterial stiffness,
arterial/heart age and cardiac fitness at the same time,
showing the effects of cardiovascular risk factors on the arteries.
Unimedic’s Arteriograph measures individual cardiovascular risk
and evaluates the efficiency of applied therapy within two minutes
In mid-September the company also launched the Arteriograph 24,
an ambulatory device which will enable central blood pressure and
arterial stiffness to be monitored over a 24-hour period.
The device is the more-advanced version of
the most accurate (BHS AA validated) and best value
for money ambulatory blood pressure monitor on the market,
the TensioDay ABPM, which comes with a professional software package.
It is an idea solution for practices wanting to comply
with the recommendations of the new NICE Hypertension Guideline
for diagnosing high blood pressure.
TensioDay ABPM helps practices to comply with new NICE guidelines
for diagnosing high blood pressure
13 July 2011Draeger UK